Tudor Investment Corp ET AL Makes New Investment in Avanos Medical, Inc. (NYSE:AVNS)

Tudor Investment Corp ET AL purchased a new stake in Avanos Medical, Inc. (NYSE:AVNS) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 32,571 shares of the company’s stock, valued at approximately $519,000. Tudor Investment Corp ET AL owned about 0.07% of Avanos Medical as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Quantbot Technologies LP purchased a new position in Avanos Medical during the 4th quarter valued at about $64,000. Tower Research Capital LLC TRC lifted its position in shares of Avanos Medical by 493.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,075 shares of the company’s stock worth $129,000 after purchasing an additional 6,714 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Avanos Medical in the fourth quarter valued at approximately $162,000. Mariner LLC grew its holdings in shares of Avanos Medical by 18.0% in the fourth quarter. Mariner LLC now owns 10,655 shares of the company’s stock valued at $170,000 after purchasing an additional 1,625 shares in the last quarter. Finally, US Bancorp DE increased its stake in Avanos Medical by 18.0% during the 4th quarter. US Bancorp DE now owns 14,093 shares of the company’s stock worth $224,000 after buying an additional 2,147 shares during the period. 95.17% of the stock is currently owned by hedge funds and other institutional investors.

Avanos Medical Stock Down 0.2 %

AVNS stock opened at $12.56 on Friday. The company’s 50 day moving average price is $13.47 and its 200 day moving average price is $16.14. The firm has a market capitalization of $577.80 million, a price-to-earnings ratio of 36.94 and a beta of 1.13. Avanos Medical, Inc. has a fifty-two week low of $11.84 and a fifty-two week high of $25.36. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.46 and a current ratio of 2.22.

Avanos Medical (NYSE:AVNS) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.07. The business had revenue of $167.50 million for the quarter, compared to analyst estimates of $161.75 million. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%. The company’s revenue was up .8% on a year-over-year basis. During the same period last year, the business earned $0.22 EPS. On average, equities research analysts anticipate that Avanos Medical, Inc. will post 1.32 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of Avanos Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, March 19th.

Insider Transactions at Avanos Medical

In related news, SVP Kerr Holbrook sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $15.25, for a total value of $106,750.00. Following the completion of the transaction, the senior vice president now directly owns 82,047 shares of the company’s stock, valued at $1,251,216.75. This represents a 7.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 2.64% of the company’s stock.

Avanos Medical Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.